Economics of stratified medicine in rheumatoid arthritis

TitleEconomics of stratified medicine in rheumatoid arthritis
Publication TypeJournal Article
Year of Publication2014
AuthorsGavan S, Harrison M, Iglesias C, Barton A, Manca A, Payne K
JournalCurr Rheumatol Rep
Volume16
Issue12
Pagination468
Date Published12/2014
ISSN1534-6307
Abstract

Clinically relevant examples of stratified medicine are available for patients with rheumatoid arthritis (RA). The aim of this study was to understand the current economic evidence for stratified medicine in RA. Two systematic reviews were conducted to identify: (1) all economic evaluations of stratified treatments for rheumatoid arthritis, or those which have used a subgroup analysis, and (2) all stated preference studies of treatments for rheumatoid arthritis. Ten economic evaluations of stratified treatments for RA, 38 economic evaluations including with a subgroup analysis and eight stated preference studies were identified. There was some evidence to support that stratified approaches to treating a patient with RA may be cost-effective. However, there remain key gaps in the economic evidence base needed to support the introduction of stratified medicine in RA into healthcare systems and considerable uncertainty about how proposed stratified approaches will impact future patient preferences, outcomes and costs when used in routine practice.

DOI10.1007/s11926-014-0468-x
Alternate JournalCurr Rheumatol Rep
PubMed ID25366935
Grant ListCDF-2009-02-21 / / Department of Health / United Kingdom
G0501892 / / Medical Research Council / United Kingdom